Related Experiment Video
Updated: Jun 2, 2026
Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer
1University of Sheffield, Jessops Hospital, Sheffield, United Kingdom.
Objective:
To report the management of a rare case of ovarian hyperstimulation syndrome (OHSS) induced by tamoxifen therapy for breast cancer in a 50-year-old woman.
Design:
Case report.
Setting:
Gynecology outpatient department of a university hospital.
Patient(S):
A 50-year-old premenopausal patient with a history of breast cancer was prescribed adjuvant treatment with tamoxifen.
Intervention(S):
Temporary discontinuation of tamoxifen therapy resolved symptoms, but resumption of tamoxifen caused a recurrence of symptoms. Surgical bilateral salpingo-oophrectomy was therefore performed.
Main Outcome Measure(S):
Resolution of symptoms of OHSS.
Result(S):
Bilateral salpingo-oophrectomy rendered the patient postmenopausal and enabled the commencement of the aromatase inhibitor anastrozole as an alternative adjuvant therapy for breast cancer.
Conclusion(S):
Tamoxifen-induced OHSS is rare. Furthermore, OHSS is very rare in the older female. OHSS usually resolves with temporary discontinuation of tamoxifen, however, the recurrence of symptoms when resuming tamoxifen is better treated with bilateral salpingo-oophorectomy to enable adjuvant treatment with anastrazole.
Related Concept Videos
02:07Oogenesis
01:24Disorders of the Female Reproductive System
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...